or large non-ST elevation myocardial infarction (NSTEMI). Study subjects were randomized within 72 hours of PCI to either ...

For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with persistent undertreatment of high-risk older patients with effective ...

Following cardiac catheterization, patients with ST-segment elevation myocardial infarction (STEMI) have a higher risk of short-term mortality than patients with non-STEMI (NSTEMI), who have a ...

For patients with either NSTEMI or STEMI, American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that intravenous unfractionated heparin (UFH) be dosed by weight ...

non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI): These are major changes since the last DAPT guideline, from 2016, which had only ...

More importantly, and less well described in the literature, is how this risk:benefit ratio plays out for patients with NSTEMI or for patients with ACS. As in the case of STEMI, the outcome of DES ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

Individual patient data were obtained from three trials, including 9130 randomized patients with ACS: 3132 with ST-segment elevation myocardial infarction (STEMI); 3023 with non-STEMI (NSTEMI ...